Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Paolo Peterlongo,Jenny Chang‐Claude,Kirsten B. Moysich,Anja Rudolph,Rita K. Schmutzler,Jacques Simard,Penny Soucy,Rosalind Eeles,Douglas F. Easton,Ute Hamann,Stefan Wilkening,Bowang Chen,Matti A. Rookus,Marjanka K. Schmidt, Frederieke H. van der Baan,Amanda B. Spurdle,Logan C. Walker,Felicity Lose,Ana-Teresa Maia,Marco Montagna,Laura Matricardi,Jan Lubiński,Anna Jakubowska,Encarna B. Gómez García,Olufunmilayo I. Olopade,Robert L. Nussbaum,Katherine L. Nathanson,Susan M. Domchek,Timothy R. Rebbeck,Banu K. Arun,Beth Y. Karlan,Sandra Oršulić,Jenny Lester,Wendy K. Chung,Alex Miron,Melissa C. Southey,David E. Goldgar,Saundra S. Buys,Ramūnas Janavičius,Cecilia M. Dorfling,Elizabeth J. van Rensburg,Yuan Chun Ding,Susan L. Neuhausen,Thomas van Overeem Hansen,Anne–Marie Gerdes,Bent Ejlertsen,Lars Jønson,Ana Osorio,Cristina Martínez‐Bouzas,Javier Benı́tez,Edye E. Conway,Kathleen R. Blazer,Jeffrey N. Weitzel,Siranoush Manoukian,Bernard Peissel,Daniela Zaffaroni,Giulietta Scuvera,Mônica Barile,Filomena Ficarazzi, Frédérique Mariette,Stefano Fortuzzi,Alessandra Viel,Giuseppe Giannini,Laura Papi,Aline Martayan,Maria Grazia Tibiletti,Paolo Radice,Athanassios Vratimos,Florentia Fostira,Judy E. Garber,Alan Donaldson,Carole Brewer, Claire Foo,D. Gareth Evans,Debra Frost,Diana Eccles,Angela Brady,Jackie Cook,Marc Tischkowitz,Julian Adlard,Julian Barwell,Lisa Walker,Louise Izatt,Lucy Side,Michael J. Kennedy,Mark T. Rogers,Mary Porteous,Patrick J. Morrison, Radka Platte,Rosemarie Davidson,Shirley Hodgson,Steve Ellis,Trevor Cole,Andrew K. Godwin,Kathleen Claes,Tom Van Maerken,Alfons Meindl,Andrea Gehrig,Christian Sutter,Christoph Engel,Dieter Niederacher,Doris Steinemann,Hansjoerg Plendl,Karin Kast,Kerstin Rhiem,Nina Ditsch,Norbert Arnold,Raymonda Varon-Mateeva,Barbara Wappenschmidt,Shan Wang-Gohrke,Brigitte Bressac-de Paillerets,Benedetto Bruno,Capucine Delnatte,Claude Houdayer,Dominique Stoppa‐Lyonnet, Francesca Damiola,Isabelle Coupier,Laure Barjhoux,Laurence Venat-Bouvet,Lisa Golmard,Nadia Boutry‐Kryza,Olga M. Sinilnikova,Olivier Caron,Pascal Pujol,Sylvie Mazoyer,Muriel Belotti, Marion Piedmonte,Michael Friedlander,Gustavo C. Rodriguez,Larry J. Copeland, Miguel de la Hoya,Pedro Pérez Segura,Heli Nevanlinna,Kristiina Aittomäki,Theo A.M. van Os,Hanne Meijers-Heijboer,Annemarie H. van der Hout,Maaike P.G. Vreeswijk,Nicoline Hoogerbrugge,Margreet G. E. M. Ausems,Helena C. van Doorn,J. Margriet Collée,Edith Oláh,Orland Díez,Ignacio Blanco,Conxi Lázaro,Joan Brunet,Lídia Feliubadaló,Cezary Cybulski,Jacek Gronwald,Katarzyna Durda,Katarzyna Jaworska–Bieniek,Grzegorz Sukiennicki,Aðalgeir Arason,Jocelyne Chiquette,Manuel R. Teixeira,Curtis Olswold, Fergus J. Couch,Noralane M. Lindor,Xianshu Wang,Csilla I. Szabo,Kenneth Offit,Marina Corines,Lauren Jacobs,Mark E. Robson,Liying Zhang,Joseph Vijai,Andreas Berger,Christian F. Singer,Christine Rappaport,Daphne Geschwantler Kaulich,Georg Pfeiler,Muy Kheng Tea, Catherine M. Phelan, Mark H. Greene, L. Phuong,Gad Rennert,Anna Marie Mulligan,Gord Glendon,Sandrine Tchatchou,Irene L. Andrulis,Amanda E. Toland,Anders Bojesen,Inge Søkilde Pedersen, Mads Thomassen,Uffe Birk Jensen,Yael Laitman,Johanna Rantala,Anna von Wachenfeldt,Hans Ehrencrona,Marie Stenmark Askmalm,Åke Borg,Karoline Kuchenbaecker,Lesley McGuffog,Daniel Barrowdale,Sue Healey,Andrew Lee,Paul D.P. Pharoah,Georgia Chenevix-Trench,Antonis C. Antoniou,Eitan Friedman

Cancer Epidemiology, Biomarkers & Prevention(2015)

引用 2|浏览7
暂无评分
摘要
Abstract Background:BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests the existence of genetic and nongenetic modifying factors. In this study, we evaluated the putative role of variants in many candidate modifier genes. Methods: Genotyping data from 15,252 BRCA1 and 8,211 BRCA2 mutation carriers, for known variants (n = 3,248) located within or around 445 candidate genes, were available through the iCOGS custom-designed array. Breast and ovarian cancer association analysis was performed within a retrospective cohort approach. Results: The observed P values of association ranged between 0.005 and 1.000. None of the variants was significantly associated with breast or ovarian cancer risk in either BRCA1 or BRCA2 mutation carriers, after multiple testing adjustments. Conclusion: There is little evidence that any of the evaluated candidate variants act as modifiers of breast and/or ovarian cancer risk in BRCA1 or BRCA2 mutation carriers. Impact: Genome-wide association studies have been more successful at identifying genetic modifiers of BRCA1/2 penetrance than candidate gene studies. Cancer Epidemiol Biomarkers Prev; 24(1); 308–16. ©2014 AACR.
更多
查看译文
关键词
ovarian cancer risk,mutation carriers,genetic
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要